Other languages Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.6831 ^USD	-5.52%		-14.84%	-51.55%

Mar. 27	Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating	MT
Mar. 26	Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	Mar. 21
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors	Feb. 08
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	Dec. 12
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Lucid Diagnostics Inc. Appoints Shaun M. O?Neil as President	Nov. 13
Lucid Diagnostics Inc. Releases Positive Data from First Prospective Clinical Utility Study of Esoguard®? Esophageal Precancer Detection	23-09-07
Lucid Diagnostics Inc. Releases Positive Data Demonstrating Clinical Utility of EsoGuard®? Esophageal Precancer Detection in Fire Fighters	23-09-06
Lucid Diagnostics to Provide Esophageal Pre-Cancer Screening to Ancira Auto Employees	23-08-24
Lucid Diagnostics Inc. Executes First Direct Employer Contract to Provide EsoGuard®? Esophageal Precancer Testing as an Employee Benefit	23-08-24
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Lucid Diagnostics Launches First Esoguard® Mobile Test Unit	23-06-05
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Lucid Diagnostics Inc. Announces Findings from Two Clinical Studies of its EsoGuard®? Esophageal DNA Test and EsoCheck®? Cell Collection Device	23-05-11
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Elon Musk's challenge: Stay ahead of the competition	23-02-24
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn	23-01-17
Sector Update: Health Care Stocks Fading in Late Tuesday Trading	22-11-15
Sector Update: Health Care	22-11-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Other languages

Filters